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Diagnosis acute GVHD chronic GVHD Previous therapy
FA Skin, gut Skin, gut, eye ,liver CTC/ CSA/ basiliximab
FA Gut, stomach Mouth, liver CTC/ CSA/ basiliximab
MDS skin skin, mouth CTC/ CSA/ AZA
MDS (second
ECP cycle)
skin CTC/ CSA/ AZA
AAS skin Skin, liver, lung CTC/ CSA/ basiliximab
FA Skin, gut, liver Skin, gut, liver CTC/ CSA /basiliximab/
MMF/Tacrolimus
ALL Skin Mouth, skin, liver, eye CTC/CSA
CML skin, liver Skin, eye, stomach,
liver, mouth, fascia
CTC/ CSA/ MMF
BDA Skin, eye,
mouth
CTC/ CSA/ basiliximab
SCID skin Skin, gut, liver CTC/ CSA/ basiliximab/
AZA/ Tacrolimus
IFN gama
deficiency
Skin, eye,
mouth
CTC/ CSA/ basiliximab
CML Skin, eye Skin, lung, eye, mouth CTC/ CSA
FA Skin, eye Skin, fascia, eye CTC/ CSA/
S312 Poster Session IIWe retrospectively analysed 22 patients (10 females e 12 males)
who received HSCT between 01/1999 and 01/2009 and devel-
oped as complicattion chronic GVHD steroid refractory or de-
pendent and who received MMF as second line therapy.
Diagnosis: Fanconi Anemia (8); Chronic Myeloid Leukemia(5);
Others(9). Cell source was marrow in 16, pheripheral blood
(pb) in 3, and cord blood in 3 patients. Eight patients received
HSCT from related and 14 from unrelated donors. Immunopro-
phylaxis was: CSA e methotrexate (MTX) (15); CSA e CTC(2);
CSA, MTX and methylprednisolone (5). All patients had exten-
sive chronic GVHD. As we reclassified them according to the
NIH consensus criteria, 15 (68%) of them had severe disease
and 7(39%) had moderate disease. Thirteen (59%) had progres-
sive, 8 (36%) had ‘‘de novo’’ and 1 (5%) quiescent GVHD. Liver,
oral mucosa and skin were the sites most frequently envolved.
Nine patients had more than 3 organs involved, 6 were using ste-
roids at the time of diagnosis and 5 had thrombocytopenia lower
than 100.000/mm3. Overall response defined by improvement in
at least one organ or estabilization of GVHD was observed in 15
(68%) patients. Eleven patients (50%) stopped steroids after a me-
dian of 16.5 months. Eight patients (36%) stopped all immunesu-
pression in a median time of 43 months. Four patients died for
reasons related to their GVHD and 3 others received another
drug for failure with MMF. We did not observe grade 2-4 toxicity
leading to suspension of the drug.
In conclusion MMF was a safe drug as therapy for chronic steroid
dependent or refractory GVHD with an overall response of 68% in
this population. Prospective trials are necessary for a better evalua-
tion of the efficacy of this drug as second line therapy for chronic
graft-versus-host-disease.basiliximab/ PUVA/
Tacrolimus/ MMF
CML skin Skin, mouth, eye, liver CTC/ CSA/ thalidomide/
AZA/ MMF
JMML Skin,
gastrointestinal
tract
CTC/ CSA/ basiliximab
CML Skin, liver Mouth, eye, liver CTC/ CSA/ Tacrolimus
AF: Fanconi anemia, SMD:myelodysplastic syndrome; AAS: severe aplas-
tic anemia; LLA: acute lymphoblastic leukemia LMC: chronic myeloid
leukemia, ABD: Diamond-Blackfan anemia, SCID: severe combined im-
munodeficiency, JMML: juvenile chronic myelomonocytic leukemia,
AZA: azathioprine; MMF: mycophenolate mofetil.420
EXTRACORPOREAL PHOTOPHERESIS IN REFRACTORY ACUTE AND/OR
CHRONIC GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION
Franco, V., Funke, V.A.M., Nunes, E.C., Setubal, D.C., Medeiros, L.,
Michels, M., Bonamin, C., Nabhan, S., Ribeiro, L., Morando, J.,
Bitencourt, M., Bonfim, C., Vieira, A.G., Loth, G., Pasquini, R.,
Neto, J.Z. Hospital de Clinicas-Federal University of Parana, Curitiba,
Parana, Brazil
Introduction:Graft- versus-host disease (GVHD) after hematopoi-
etic stem cell transplantation (HSCT) is associated with high mor-
bidity and mortality rates. Corticosteroids and calcineurin
inhibitors are the first line treatment of GVHD.There are many sec-
ond line therapies with few controlled studies. Extracorporeal Pho-
topheresis (ECP) is an immunomodulatory treatment which has
recently been proof as steroid sparing procedure (Flowers et al,
Blood. 2008 Oct 1;112(7):2667-74)
Objective:We describe our experience at the Hospital de Clınicas
from the Federal University of Parana- Brazil, with ECP in pa-
tients with steroid refractory or dependent acute or chronic
GVHD.
Patients andMethods:We reviewed between Februray 2002 and
June, 2009, the data of 19 patients who received allogeneic he-
matopoietic stem cell transplantation (HSCT) and developed
as complication acute and/or cronic GVHD refractory to corti-
costeroids and cyclosporine therapy and were then treated with
ECP (20 procedures: one patient had been submitted twice).
Four patients were excluded because they had received less
than six sessions; fifteen patients were evaluated (female:13
male:2). The mean age at HSCT was 11 years (range 3 to 49).
Partial response was defined by an improvement in at least one
involved organ and complete response as resolution of all symp-
toms of GVHD. The clinical characteristics of these patients are
in Table 1.
Results:Median overall survival afterHSCTwas 2 years (range 3 m-
13y). Five patients were submitted to ECP due to acute GVHD and
13 due to chronic GVHD (2 patients had overlap syndrom
GVHD.Three of 5 patients with acute GVHD (60%) had total re-
sponse, 1 (20%) partial response and 1 (20%) had no response.
Nine of 13 patients with chronic GVHD (70%) had partial response,
2 (15%) total response and 2 (15%) had no response. Ten patients(67%) reduced the dosage of corticosteroid to less than 0,5 mg/kg/d.
There were no severe adverse effects related to ECP.
Conclusion: ECP is an effective alternative in the treatment of
GVHD in this study, with no severe adverse effects observed. The
procedure allowed reduction of corticosteroids in 67% of our pa-
tients. Prospective trials are necessary for a more precise evaluation
of this procedure in GVHD therapy.421
SOLUBLE HUMAN LEUKOCYTE ANTIGEN G (SHLA-G) IN HEMATOPOIETIC
CELL TRANSPLANTATION IS ASSOCIATED WITH SEVERAL CLINICAL
COMPLICATIONS AFTER TRANSPLANT
Waterhouse, M., Duque-Afonso, J., Samek, E., Bertz, H., Finke, J.
Freiburg University Medical Center, Freiburg, Baden Wuettemberg,
Germany
HLA-G is a non classical class I HLA molecule with low level of
polymorphisms and with 7 isoforms, 4 are membrane bound and 3
are soluble. Another differential characteristic is it is tissue restricted
and have been described in adult thymic medulla, cornea, pancreatic
islet and endothelial cell precursors. Several immune modulatory
functions have been attributed to this molecule such as the interac-
tion between B, T,NK and antigen presenting cells. Due to their im-
munomodulatory properties we investigated the possible role of
soluble HLA-G (sHLA-G) in the allogeneic hematopoietic cell
transplantation (HCT) setting. A cohort of 37 patients, who under-
went HCT, were studied, 13 patients had acute myeloid leukemia, 8
patients had myelodisplastic syndromes (preleukemia disease) while
the rest of the patients had non myeloid malignancies. Twenty eight
patients received reduce intensity conditioning regimen, while the
rest of the patients received myeloablative conditioning treatment.
Plasma samples from all patients were obtained before the condition-
ing regimen and after transplant at different timepoints. Soluble
HLA-G concentration was measured in duplicates of plasmas by
a specific enzyme-linked immunosorbent assay (ELISA) using the
MEMG/9 as the capture antibody. Pre transplant variables were
age, gender, disease, type of transplant (related, unrelated), infused
marrow cell dose and donor gender. Post transplantation variables
Poster Session II S313were graft versus host disease (acute/chronic, grade, day of onset,
affected organ), infections, survival, relapse, day of bone marrow re-
generation and immunosuppression therapy.We found a statistically
significant association between rising levels of HLA-G during trans-
plantation and clinically relevant (grade II-IV) acute GvHD, infec-
tious events after transplantation, in particular fungal infections,
and development of chronic GvHD. Our preliminary data shows
that sHLA-G molecules are involved in several complications after
allogeneic hematopoietic cell transplantation.Bronquiolitis Obliterans- Patient Characteristics
CHARACTERISTICS N5 50
age 25 (2 – 50)
Recipient M / Donor F 20(40%)
Donor and recipient match
matched 40 (80%)
Source of stem cell
BM 46 (92%)
other (PB or CB) 4(8%)
Donor
related 45 (90%)
unrelated 5 (10%)
Diagnosis
CML 24 (48%)
AML 8 (16%)
ALL 5 (10%)
Fanconi Anemia 5 (10%)
Others 8 (16%)
Chronic GVHD onset
progressive 19 (38%)
quiescent 19 (38%)
de novo 8 (16%)422
AN IN-VIVO MODEL OF HUMAN T CELL-MEDIATED REJECTION OF ALLO-
GENEIC MISMATCHED HEMATOPOIETIC CD34 + STEM CELLS USING
NOD/SCID GNULL (NOG) MICE
Nicolini, B., Mahmud, D., Mahmud, N., Nucifora, G., Rondelli, D.
University of Illinois at Chicago
Anti-humanCD34+ cell T cell alloreactivity was previously shown
in-vitro. In this study we transplanted human CD34+ cells and allo-
geneic T cells in a NOD/SCID gnull (NOG) mouse model to evalu-
ate the occurrence of stem cell rejection in-vivo. After sublethal
irradiation NOG mice received 2105 CB CD34+ cells and alloge-
neic blood T cells at 1:0 (control), 1:2, or 1:10 CD34+ cell: T cell ra-
tio (n5 5-10 mice per group). Human cell engraftment was assessed
in the bone marrow and in the spleen 6 weeks following transplanta-
tion. Marrow engraftment of huCD45+ cells was 606 10% in con-
trol mice and included B cells (646 4%), CD34+ cells (186 1%),
CD33+ myeloid cells (76 1%), CD14+ monocytes (36 1%). In
contrast, mice that were transplanted with CD34+ cells and low
dose (1:2 ratio) or high dose (1:10 ratio) allo-T cells had only
96 2% and 36 1% huCD45+ cells, respectively, in the bone mar-
row (p5 0.01) and .98% were huCD3 +T cells. Spleen engraft-
ment of huCD45+ cells was lower (256 8%) in control mice (1:0
ratio) as compared to 666 10% and 366 11% in 1:2 and 1:10
groups, respectively (p5 0.05). However, also the spleen of mice re-
ceiving CD34+ and T cells included .98% CD3 +T cells. Among
the T cells, both in the marrow and in the spleen of mice in the
1:2 and 1:10 ratio groups, 60-70% were CD4 +CD8- cells, 22-
25% CD8 +CD4- cells, 1-3% CD56+ cells, and 2-5%
CD4 +CD25+ cells. Only in mice receiving low doses of T cells,
on average 126 6% of the T cells in the bone marrow and spleen
were CD4 + CD8+. Mice receiving high doses of T cells had acute
xenogeneic GVHD demonstrated by fur changes, reduced survival
(p5 0.02) and weight loss (p5 0.0001) compared to control mice
or mice receiving a lower dose of T cells (1:2 ratio). In-vitro mixed
leukocyte cultures with irrad CD34+ cells and allogeneic T cell re-
sponders (R) at the same ratio as in in-vivo experiments were then
performed w/wo the addition of CD4 +CD25+ regulatory T cells
(Tregs) at 1:1 or 1:5 Treg: R ratio. Since a 60% T cell suppression
was observed only with equal numbers of Tregs and allo-responders,
we are currently testing whether auto or allo Tregsmay prevent stem
cell rejection in NOG mice transplanted with CD34+ cells, alloge-
neic T cells and Tregs at 1:2:2 or 1:1:2 ratio. NOG mice represent
a useful model to study human T cell mediated bone marrow failure
or stem cell rejection and will allow us to investigate new strategies of
allogeneic transplantation with subsets of T cells or hematopoietic
stem cells.after DLI 3 (6%)
Risk characteristics
platelets less than 100.000/mm3 21 (42%)
.3 organs 27 (54%)
\1500 lymphocytes 39 (78%)
NIH global scoring
Moderate 14 (28%)
Severe 36 (72%)423
BRONCHIOLITIS OBLITERANS AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION – AN ANALYSIS OF 50 CASES OVER THIRTY YEARS AT A SIN-
GLE BRAZILIAN INSTITUTION
Vieira, A.G., Funke, V.A.M., Nunes, E.C., Setubal, D.C., Medeiros, L.,
Michels, M., Ribeiro, L., Morando, J., Bonamin, C., Nabhan, S.,
Bitencourt, M.A., Bonfim, C., Loth, G., Franco, V., Pasquini, R.,
Neto, J.Z. Hospital de Clinicas Federal University of Parana, Curitiba,
Parana, BrazilIntroduction: Bronchiolitis obliterans (BO) is a late complication of
hematopoietic stem cell transplantation (HSCT) usually associated
with chronic graft versus host disease (C-GVHD) and often fatal.
We describe here characteristics and clinical course of 50 patientsat a brazilian transplant center who developed bronchiolitis obliter-
ans as a manifestation of chronic graft versus host disease.
Patients andMethods:We searched the database and reviewed the
medical records of 1645 patients who received HSCT between 1979
and 2009, and identified 50 patients who developed BO, whose clin-
ical features and clinical course were analyzed retrospectively. The
diagnosis of BOwas determined by either the presence of an obstruc-
tive ventilatory defect on a pulmonary function test or a chest CT
showing small airways wall thickening or air trapping associated
with a typical clinical picture in the context of a patient with C-
GVHD. NIH criteria were used to define the severity of C-GVHD.
Results:TheprevalenceofBOin these30yearswas 3%.Patient char-
acteristics are summarized inTable 1.According to the severity of pul-
monary involvement 14 patients (28%) had score 1, 12 (24%) had
score 2, and 22 (44%) had score 3. Median time between transplanta-
tion and diagnosis ofC-GVHDwas 138 days (33-3738), whilemedian
time between the diagnosis of C-GVHD and the diagnosis of BOwas
77days (0 –1752).Median timebetween transplantationanddiagnosis
of BOwas 343 days (38 – 3877). Twenty-nine patients (58%) required
second-line treatment due to lack of response. The main secondary
treatments used were: thalidomide(11); azathioprine(18), tacrolimus
(7); mycophenolatemofetil (7) and photopheresis (1).Median survival
for this group was 1637 days (195 – 6102). At the time of this analysis
23 (46%) patients had died from BO related causes.
Conclusion: Bronchiolitis obliterans was a serious late complica-
tion, occurring in 3% of patients transplanted in our center over
the past 30 years. Mortality rate was high (46%) and most patients
(58%) did not respond to primary therapy. Better understanding of
the pathophysiology of C-GVHD is necessary for the development
of more effective therapeutic tools.424
PKCQ IS REQUIRED FOR ALLOREACTIVITY AND GVHD BUT NOT FOR
IMMUNE RESPONSES TOWARD LEUKEMIA AND INFECTION IN MICE
Yu, X.-Z.1, Valenzuela, J.O.1, Iclozan, C.A.1, Blazar, B.R.2,
Waller, E.K.3, Beg, A.A.1 1Moffitt Cancer Center, Tampa, FL; 2Univer-
sity of Minnesota, Minneapolis, MN; 3Emory University School of Medi-
cine, Atlanta, GA
